Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Emergency Medicine and Critical Care
- Ophthalmology
- Women’s Health Care
- Sleep Medicine and Disorders
- Nuclear Medicine
- Forensic and Legal Medicine
- Psychiatry and Mental Health
- Cancer Clinic
Abstract
Citation: Ann Clin Case Rep. 2023;8(1):2474.DOI: 10.25107/2474-1655.2474
Llama-Derived Single-Chain Antibody for Targeting CD20 in B-Cell Lymphoma
Lu Y1, Li S2,3 and Wu W4*
1Neonatal Intensive Care Unit, The Second Hospital of Tianjin Medical University, China
2College of Life Sciences and Health, Wuhan University of Science and Technology, China
3Beijing Novaboody Biotechnological Ltd, China
4Department of Blood Transfusion, The 960th Hospital of the PLA Joint Logistics Support Force, China
PDF Full Text Research Article | Open Access
Abstract:
Objective: Since the approval of rituximab for the treatment of B cell non-Hodgkin lymphoma, the development of monoclonal Antibodies (mAbs) for cancer treatment has been subject to intense investigations. However, rituximab is expensive and has limited availability. Llama-derived singlechain antibody fragments are small molecules with several advantages over conventional antibodies, which have been widely used for cancer treatment. The present study aims to obtain a single-domain anti-CD20 antibody from an immune Llama phage display library. Methods: An immune Llama phage display library was constructed with phage display technology. The anti-CD20 single-domain Antibodies (sdAbs) were selected and the genes were cloned into expression vector pSJF2. The antibodies were efficiently expressed in Escherichia coli. The affinity and in vitro biological functions of different anti-CD20 sdAbs were measured by Biolayer interferometry. Result: Three anti-CD20 single-domain antibodies (anti-CD20e7, anti-CD20b1 and anti-CD20f1) were obtained which were produced at high yield in Escherichia coli and showed high affinity. Conclusion: These results, together with the ease of production, show that anti-CD20 VHHs are valuable candidates for the development of B-cell lymphoma therapies.
Keywords:
B-cell lymphoma; Immune phage display library; Llama-derived single-chain antibody fragments
Cite the Article:
Lu Y, Li S, Wu W. Llama-Derived Single-Chain Antibody for Targeting CD20 in B-Cell Lymphoma. Ann Clin Case Rep. 2023; 8: 2474..
